Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2010 Dec;71(6):345–359. doi: 10.1016/S0011-393X(10)80001-3

Effects of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide topical emulsion in Thai adults with melasma: a single-center, randomized, double-blind, controlled study

Jarupa Viyoch 1,2,*, Isaree Tengamnuay 3, Khemjira Phetdee 1, Punpimol Tuntijarukorn 2, Neti Waranuch 1,2
PMCID: PMC3969619  PMID: 24688154

Abstract

Background: Melasma is an acquired hyperpigmentary disorder characterized by dark patches or macules located on the cheeks, forehead, upper lip, chin, and neck. Treatment of melasma involves the use of topical hypopigmenting agents such as hydroquinone, tretinoin, and azelaic acid and its derivatives.

Objective: The purpose of this study was to assess the efficacy of a formulation containing a combination of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide compared with an emulsion-based control in the treatment of melasma in Thai adults.

Methods: In this single-center, randomized, double-blind, controlled study, Thai patients with mild to moderate facial melasma (relative melanin value [RMV] in range of 20–120) were randomized for the application of either the test or the emulsion-based (control) product in the morning and before bedtime for 8 weeks. The supplemental sunscreen product with sun protection factor 30 was distributed to all patients. Subjects were assessed for the intensity of their hyperpigmented skin area by measuring the difference in the absolute melanin value between hyperpigmented skin and normal skin (RMV). This parameter was used as a primary outcome of this study. Additionally, the severity of melasma was determined visually using the Melasma Area and Severity Index (MASI) scored independently by 3 investigators. The assessments of melasma intensity and other skin properties were performed before administration (week 0) and every 2 weeks thereafter for up to 8 weeks. Other skin properties, including moisture content, pH, and redness (erythema value), were measured. Adverse events (AEs), including erythema, scaling, and edema, were also assessed by a dermatologist using the visual grading scale of Frosch and Kligman and COLIPA.

Results: The resulting primary intent-to-treat (ITT) population included 33 patients in the test group and 34 patients in the control group. Sixty patients completed all 8 weeks of the study (on-treatment [OT] population): 91% (30) of the 33 patients in the test group, and 88% (30) of the 34 patients in the control group. Between-group differences in mean RMV were statistically significant at week 6 in both the primary ITT (P = 0.005) and OT (P = 0.006) populations. The significant differences in mean MASI scores between the test and the control groups were initially observed at weeks 4 (P = 0.005) and 8 (P = 0.027) in the OT and primary ITT populations, respectively. Other parameters, including skin pH, erythema, and moisture content did not significantly change from baseline at any time point of study. The incidence of AEs was not different between the test (4/33 [12%]) and control (5/34 [15%]) groups.

Conclusions: The significant differences in RMVs between the test and control groups were observed after 6 weeks of treatment, both in the primary ITT and OT populations. The incidence of patients with AEs was not significantly different between the test and control groups.

Key words: trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide, melasma, Thai adults

Full Text

The Full Text of this article is available as a PDF (112.0 KB).

References

  • 1.Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91–98. doi: 10.1016/s0733-8635(05)70150-9. [DOI] [PubMed] [Google Scholar]; Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:ix. doi: 10.1016/s0733-8635(05)70150-9. [DOI] [PubMed] [Google Scholar]
  • 2.Lawrence N, Cox SE, Brody HJ. Treatment of melasma with Jessner's solution versus glycolic acid: A comparison of clinical efficacy and evaluation of the predictive ability of Wood's light examination. J Am Acad Dermatol. 1997;36:589–593. doi: 10.1016/s0190-9622(97)70248-2. [DOI] [PubMed] [Google Scholar]
  • 3.Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453–1457. doi: 10.1001/archderm.131.12.1453. [DOI] [PubMed] [Google Scholar]
  • 4.Sanchez NP, Pathak MA, Sato S. Melasma: A clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698–710. doi: 10.1016/s0190-9622(81)70071-9. [DOI] [PubMed] [Google Scholar]
  • 5.Pichardo R, Vallejos Q, Feldman SR. The prevalence of melasma and its association with quality of life among adult male migrant Latino workers. Int J Dermatol. 2009;48:22–26. doi: 10.1111/j.1365-4632.2009.03778.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Balkrishnan R, Mcmichael AJ, Camacho FT. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572–577. doi: 10.1046/j.1365-2133.2003.05419.x. [DOI] [PubMed] [Google Scholar]
  • 7.Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol. 2006;55:1048–1065. doi: 10.1016/j.jaad.2006.02.009. [DOI] [PubMed] [Google Scholar]
  • 8.Rendon M, Berneburg M, Arellana I. Treatment of melasma. J Am Acad Dermatol. 2006;54:S272–S281. doi: 10.1016/j.jaad.2005.12.039. [DOI] [PubMed] [Google Scholar]
  • 9.Cestari T, Adjadj L, Hux M. Cost-effectiveness of a fixed combination of hydroquinone/ tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. J Drugs Dermatol. 2007;6:153–160. [PubMed] [Google Scholar]
  • 10.Maeda K, Naganuma M. Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. J Photochem Photobiol. 1998;47:136–141. doi: 10.1016/s1011-1344(98)00212-7. [DOI] [PubMed] [Google Scholar]
  • 11.Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: An updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006;19:550–571. doi: 10.1111/j.1600-0749.2006.00334.x. [DOI] [PubMed] [Google Scholar]
  • 12.Maramaldi G, Esposito MA. Potassium azeloyl diglycinate: A multifunctional skin lightener. Cosmet Toilet. 2002;117:43–50. [Google Scholar]
  • 13.Rigano L, Cucchiara M. Azeloyl diglycinate: A new active in skin disequilibrium. J Appl Cosmetol. 2003;21:177–188. [Google Scholar]
  • 14.Personal Care . Azelaic acid derivative whitening efficacy studied. January 2007. http://www.personalcaremagazine.com/Story.aspx?Story=1903 Accessed May 18, 2010. [Google Scholar]
  • 15.Hakozaki T, Minwalla L, Zhuang J. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:20–31. doi: 10.1046/j.1365-2133.2002.04834.x. [DOI] [PubMed] [Google Scholar]
  • 16.Yoshimura K, Harii K, Aoyama T. A new bleaching protocol for hyperpigmented skin lesions with a high concentration of all-trans retinoic acid aqueous gel. Aesthetic Plast Surg. 1999;23:285–291. doi: 10.1007/s002669900285. [DOI] [PubMed] [Google Scholar]
  • 17.Yoshimura K, Harii K, Aoyama T, Iga T. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg. 2000;105:1097–1108. doi: 10.1097/00006534-200003000-00040. discussion. [DOI] [PubMed] [Google Scholar]; Yoshimura K, Harii K, Aoyama T, Iga T. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg. 2000;105:1109–1110. doi: 10.1097/00006534-200003000-00040. [DOI] [PubMed] [Google Scholar]
  • 18.Griffiths CE, Finkel LJ, Ditre CM. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled clinical trial. Br J Dermatol. 1993;129:415–421. doi: 10.1111/j.1365-2133.1993.tb03169.x. [DOI] [PubMed] [Google Scholar]
  • 19.Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner's solution chemical peels. Dermatol Surg. 2006;32:1429–1436. doi: 10.1111/j.1524-4725.2006.32352.x. [DOI] [PubMed] [Google Scholar]
  • 20.Zhai H, Hannon W, Hahn GS. Strontium nitrate suppresses chemically-induced sensory irritation in humans. Contact Dermatitis. 2000;42:98–100. doi: 10.1034/j.1600-0536.2000.042002098.x. [DOI] [PubMed] [Google Scholar]
  • 21.Frosch PJ, Kligman AM. The soap chamber test. A new method for assessing the irritancy of soaps. J Am Acad Dermatol. 1979;1:35–41. doi: 10.1016/s0190-9622(79)70001-6. [DOI] [PubMed] [Google Scholar]
  • 22.Maenthaisong R, Viyoch J, Chaiyakunapruk N, Warnnissorn P. Cleansing lotion containing tamarind fruit pulp extract. II. Study of cumulative irritation effects in humans. J Cosmet Dermatol. 2007;6:178–182. doi: 10.1111/j.1473-2165.2007.00328.x. [DOI] [PubMed] [Google Scholar]
  • 23.Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70:563–569. doi: 10.1006/exer.1999.0819. [DOI] [PubMed] [Google Scholar]
  • 24.Lowe NJ, Rizk D, Grimes P. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20:945–959. doi: 10.1016/s0149-2918(98)80076-3. [DOI] [PubMed] [Google Scholar]
  • 25.Eberlein-König B, Schäfer T, Huss-Marp J. Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children. Acta Derm Venereol. 2000;80:188–191. doi: 10.1080/000155500750042943. [DOI] [PubMed] [Google Scholar]
  • 26.Baranda L, González-Amaro R, Torres-Alvarez B. Correlation between pH and irritant effect of cleansers marketed for dry skin. Int J Dermatol. 2002;41:494–499. doi: 10.1046/j.1365-4362.2002.01555.x. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES